4β7, on donor T cells in mesenteric lymph
nodes, and augmented the accumulation of pro-inflammatory CD4 + and CD8 + T cells within the gut mucosa, leading to a selective exacerbation of colonic GVHD and increased overall mortality.
Conversely, depletion of RA in recipient mice by vitamin A deprivation resulted in a dramatic reduction of gut homing molecule expression on donor T cells after HSCT. Significantly, absence of the retinoic acid receptor-α on donor T cells markedly attenuated the ability of these cells to cause lethal GVHD and this observation was attributable to a significant reduction in pathological damage within the colon.
These findings identify an organ-specific role for RA in GVHD, and provide evidence that blockade of the RA signaling pathway may represent a novel strategy to mitigate the severity of colonic GVHD.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially life-saving therapeutic modality for patients with hematological malignancies and non-malignant disorders. Successful outcomes, however, are compromised by graft-versus-host disease (GVHD) which remains the major complication of this treatment and the leading cause of morbidity and mortality. [1] [2] [3] GVHD is induced by donor T cells recognizing host alloantigens expressed by host antigen presenting cells (APCs). 4, 5 This results in the activation and expansion of donor T cells leading to pro-inflammatory cytokine production and the induction of cytotoxic T cell responses which both lead to tissue damage. 2, 3, 6 Acute GVHD typically develops in a restricted set of organs including the skin, liver and gastrointestinal tract. Of these target organs, the gastrointestinal tract is of particular importance. 7 Compelling data in experimental animal models indicate that the gut is not only a major target organ of GVHD, but plays a crucial role in the amplification of systemic GVHD severity. 3, 8, 9 Clinically, involvement of the gastrointestinal tract in patients with acute GVHD is a major cause of morbidity and mortality.
The gut-associated lymphoid tissue (GALT), which consists of Peyer's patches (PPs), mesenteric lymph nodes (MLNs), and lymphoid cells in the lamina propria and epithelium, is not only responsible for eliciting, but also regulating, immune responses in the intestinal mucosa. 10 The adaptive immune responses that occur in the gut are modulated by a complex interplay of regulatory mechanisms within these lymphoid tissue sites. Recently, all-trans retinoic acid (RA) has emerged as a critical regulator of gut immunity. 11 RA is an active metabolite of vitamin A that is involved in many important biological processes in vivo. 12, 13 Within the immune system, RA influences many immune cell lineages and regulates an array of immune responses in vivo. 11 RA is produced by a population of CD103 + dendritic cells in the gut and plays a pivotal role in the regulation of inflammation within the colon. 14, 15 RA is also able to enhance the stability of Foxp3 in natural Tregs (nTregs) 16 and facilitate the conversion of
─ T cells into induced Tregs (iTregs) by up-regulating Foxp3. [17] [18] [19] Recent studies have [20] [21] [22] Thus, RA appears able to alter the balance between effector and regulatory arms of the immune system similar to what has been described for blockade of IL-6 signaling. 23 Additionally, RA has been shown to augment the expression of gut-homing receptors, such as CCR9 and α4β7 on T cells under steady state conditions, 24 and mediate the recruitment of Tregs into sites of inflammation. 25 The ability to drive gut homing along with the capacity to stabilize nTreg function and facilitate the induction of iTregs, even in the presence of inflammation, suggests that administration of RA might be a strategy to reduce inflammatory responses during GVHD, particularly within the colon microenvironment. The purpose of the current study was therefore to define the role of RA in the pathophysiology of GVHD and to determine to what extent endogenous and exogenous RA was able to modulate the balance between inflammation and tolerance during GVH reactivity.
MATERIAL AND METHODS
Mice. C57BL/6 (B6; H-2 b ), Balb/cJ (H-2 d ) mice, C.129S7 Rag-1 (Balb/c Rag), and B6 Foxp3 EGFP animals 26 were purchased from The Jackson Laboratory (Bar Harbor, ME) or bred in the Animal
Resource Center (ARC) at the Medical College of Wisconsin (MCW). RAR-α-deficient (RAR-α ─ /─ ) mice (B6129 background) were kindly provided by Dr. Pierre Chambon (IGBMC, Strasbourg, France).
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Vitamin A-deficient (VAD) and vitamin A-sufficient (VAS) mice were generated as previously described. 28 All animals were housed in the Association for Assessment and Accreditation of Laboratory Reagents. All-trans retinoic acid (RA) was purchased from Sigma-Aldrich (St Louis, MO), dissolved in DMSO at a concentration of 100 mM, and stored as aliquots at -20°C. The RAR-α agonist, AM80, and the RAR-α antagonist, BMS 195614, were purchased from TOCRISbioscience (Ellisville, MO) and used at the concentrations indicated.
Bone marrow transplantation. Bone marrow (BM) was flushed from donor femurs and tibias with Dulbecco's Modified Eagle Medium (DMEM) (Gibco-BRL, Carlsbad, CA) and passed through sterile mesh filters to obtain single-cell suspensions. Host mice were conditioned with total body irradiation administered as a single exposure at a dose rate of 74 cGy using a Shepherd Mark I Cesium Irradiator (J.
L. Shepherd and Associates, San Fernando, CA). Irradiated recipients received a single intravenous injection in the lateral tail vein of BM with or without added spleen cells.
Leukemia model. A20 murine lymphoma cells of Balb/c background (H-2 d ) were obtained from the American Type Culture Collection and transfected with firefly luciferase as previously described. 29 For in vivo bioluminescence imaging (BLI), mice were given an intra-peritoneal injection of luciferin (150 mg/kg body weight) and then anesthetized with isoflurane gas using a Xenogen XGI Gas Anesthesia System (Perkin Elmer, Waltham, MA) and imaged using the IVIS Imaging system to assess bioluminescence 10 minutes after injection of the substrate. Imaging data were analyzed with Living Image Software (Xenogen).
Cell sorting and flow cytometry. Spleen cells were collected from naive mice or BMT recipients and sorted on a FACSAria (Becton Dickinson, Mountain View, CA). Sort purity for these studies consistently averaged 98% to 99%. Cells were isolated from spleen, lymph nodes, and GVHD target organs (liver, lung, and colon) of transplant recipients as described previously 23 MV70, rat IgG2b), FITC-anti-H-2Kb (clone AF6-88.5, mouse IgG2a), PE-Cy5-anti-CD4 (clone RM4-5, rat IgG2a), PE-Cy5-anti-CD8 (clone 543-6.7, rat IgG2a), PE-anti-TCRβ (clone H57-597, hamster IgG), APC-antiCD8a (clone 53-6.7, rat IgG2a), PE-anti-CD4 (clone GK1.5, rat IgG2b), FITC-anti-CD8a (clone 53-6.7, rat IgG2a), FITC-anti-IFN-γ (clone XMG1.2, rat IgG1), and PE-anti-IL-17 (clone TC11-18H10, rat IgG1) were all purchased from BD Biosciences (Franklin Lakes, NJ). FITC-anti-CCR9 (clone CW-1.2, mouse IgG2a), APC-anti-CCR9 (clone CW-1.2, mouse IgG2a), and PE-anti-α4β7 (clone DATK32, rat IgG2a) were obtained from eBioscience (San Diego, CA). Intracellular cytokine staining for IFN-γ and IL-17 was performed as described. 23 In some experiments, cells were labeled with CellTrace Violet Histological analysis. Representative samples of liver, colon, tongue, and lung were obtained from transplant recipients and fixed in 10% neutral-buffered formalin. Samples were then embedded in paraffin, cut into 5-μm-thick sections, and stained with hematoxylin and eosin. One-two sections per organ were evaluated. A semiquantitative scoring system was used to account for histological changes in the colon, liver, and lung as previously described. 30, 31 The scoring system employed to define the severity of GVHD in the tongue denoted 0 as normal, 1 as mononuclear cell infiltration into the dermis and stroma, 2 as inflammatory cells extending into the epithelium, and 3 as blistering or ulceration present in the epidermis. All slides were coded and read in a blinded fashion. Images were visualized using a Nikon Eclipse E400 microscope and a Nikon Plan APO 10X/0.45 objective lens (Nikon, Tokyo, Japan).
Image acquisition was performed with a Zeiss Axiom camera and Axiovision 3.0.6 SP2 software (Zeiss, Berlin, Germany). The dose, route, and administration schedule were derived from previously published studies that had demonstrated potent immune effects in vivo. 22, 35 Unexpectedly, we observed significantly accelerated GVHD-associated mortality in RA-treated mice compared with DMSO-treated animals (p< 0.0001; Figure 1A ). This was accompanied by more weight loss over the first four weeks which corresponded to the period of time when both groups could be comparably assessed given the early mortality in RAtreated mice ( Figure 1B ). Histological examination of GVHD target organs (colon, liver, and lung) and the tongue which served as a surrogate for skin damage 36 was performed 5 weeks after transplantation in separate experiments. There was a significant increase in pathologic damage in the colons of RA-treated mice compared with DMSO-treated animals (9.7 ± 0.8 versus 3.3 ± 0.9, p<0.001), whereas there was no significant difference in pathology scores in either the liver, tongue or lung ( Figures 1C, 1D ).
Administration of RA to animals reconstituted with BM only resulted in no mortality and pathological analysis showed no evidence of GVHD in the colon at 90 days post transplantation (data not shown).
Thus, the detrimental effect of RA was dependent upon the presence of alloreactive donor T cells. These studies demonstrated that exogenous RA administration exacerbates GVHD lethality and augments GVHD-associated damage within the colon microenvironment.
RA enhances gut-homing molecule expression on donor T cells in mesenteric lymph nodes. The acquisition of tissue-homing molecule expression on T cells after activation in secondary lymphoid
tissues is important in determining the subsequent migration pattern of effector T cells into non-lymphoid tissues. 37, 38 Recent studies have demonstrated that an important biological function of RA is to induce the expression of gut-homing molecules, α 4β7 and CCR9, on T cells under steady state conditions. 24 Since
we observed a significant enhancement of colonic damage in RA-treated mice, we sought to determine whether RA exposure resulted in increased expression of these molecules. We first addressed this question using a mixed lymphocyte culture to mimic the in vivo alloimmune response. Culture in the presence of physiological concentrations of RA (10 nM has been shown to represent a specific gut-destructive T-cell population, 41 was also significantly augmented (nine-fold) in the colons of RA-treated mice (mean 1.0 x 10 3 versus 0.11 x 10 3 ) ( Figure 3C ).
We also examined the effects of RA on Treg reconstitution using Foxp3 EGFP reporter mice as donors for transplantation. We observed that there was a significant increase in the absolute number of Tregs in the colon of RA-treated mice as well ( Figure 3D ). However, the increase in Tregs (three-fold, mean 0.022 x 10 4 versus 0.07 x 10 4 ) was noted to be more modest than was observed for T H 1, T H 17 and CD8 + T cells.
Notably, there was a corresponding increase in the percentage of CD4 + and CD8 + T cells that expressed α 4β7 in the colon indicating that these cells are indeed able to traffic to the colon. Since CCR9 has been show to be important in directing T cell trafficking into the small intestines, we examined this tissue site and observed an increased percentage of CCR9-expressing T cells in RA-treated mice ( Figure 3E ).
Collectively, these data indicated that RA administration resulted in a significant increase in the absolute number of pro-inflammatory donor T cells in the colon without a proportional increase in the Treg compartment, resulting in a more pronounced imbalance between the effector and regulatory arms of the immune system. Figure 5D ). Finally, BMS195614 abrogated the RA-induced increase in T cell proliferation ( Figure 5E ). These studies demonstrated that an RAR-α agonist could replicate the augmentation of gut-homing molecule expression observed with RA, and that this effect could be blocked by specific antagonism of the RAR-α pathway.
Vitamin-
For Figures 5A, 5B ).
There was also no difference in proliferation of CD4 + or CD8 + T cells in response to alloantigen between the two donor types (Supplementary Figure 5C) . These results demonstrated that abrogation of RA signaling through RAR-α in donor T cells markedly diminished their capacity to cause lethal GVHD, and that this was attributable to selective protection in the colon. Despite the reduction in GVHD, animals transplanted with marrow grafts from RAR-α ─ /─ donors retained their ability to mount a GVL response and had significantly longer survival when compared to leukemia or GVHD control mice ( Figure 7E ).
Moreover, bioluminescence imaging studies confirmed that these animals were free of tumor at the conclusion of these studies. 
DISCUSSION
Severe GVHD of the gastrointestinal tract is primarily responsible for much of the morbidity and mortality that is observed in experimental murine models and BMT patients. In this report, we have identified RA as a novel and critical factor in the induction of gastrointestinal GVHD. In gain-of-function studies, we found that exposure of recipient mice to exogenous RA not only failed to ameliorate the severity of GVHD, as we had initially postulated, but selectively exacerbated colonic GVHD, resulting in significantly increased mortality in recipient mice. This observation was associated with enhanced generation of gut-tropic, donor T cells in the MLNs early after BMT and an increased influx of proinflammatory donor T cells into the gut mucosa during later stages of disease development. Conversely, vitamin A deprivation, which resulted in RA deficiency in recipient mice, inhibited the acquisition of the gut-homing molecules CCR9 and α 4β7 on donor T cells after BMT, confirming a role for RA in this process. Importantly, genetic ablation of RAR-α signaling on donor T cells markedly attenuated the ability of these cells to cause GVHD lethality and, more specifically, colonic GVHD which was associated with a significant reduction in donor CD4 + and CD8 + T-cell accumulation in this tissue. Thus, these results demonstrated that RA facilitates the initiation and progression of gastrointestinal GVHD and thereby has an important pro-inflammatory role in GVHD biology.
Trafficking of donor T cells after in vivo infusion is an important aspect of GVHD pathophysiology since these cells exert their pathogenic effect only after infiltrating into target organs. 39 The acquisition of guthoming molecules on donor T cells is essential for them to migrate specifically to the gut mucosa. The important role of the integrin α 4β7 in the pathogenesis of gastrointestinal GVHD has been well demonstrated in experimental BMT models. Specifically, Petrovic and colleagues 45 showed that recipients of sort-purified α 4β7-negative donor T cells had significantly less GVHD-associated morbidity 
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GVHD. Rodent models of BMT use highly inbred experimental mice that are typically fed with commercially available diets that are well supplemented with vitamin A. This is in contrast to humans who consume highly variable diets and who therefore may have more variability in nutritional status, and hence vitamin A levels. Our results suggest that recipient vitamin A levels could be a heretofore unrecognized variable that influences the severity of GVHD in the GI tract after allogeneic BMT. Future studies will be of interest to determine if there is a correlation between recipient vitamin A levels and the severity of GVHD within this tissue site.
We observed that RAR-α signaling was important in mediating the effects of RA. The concomitant increase in RAR-α gene expression in donor CD4 T cells and endogenous RA production in the colon early after allogeneic BMT suggests that RA acts directly on T cells to modulate their function through RAR-α. However, since RAR is broadly expressed by many cell types, it is formally possible that RA can act on other cells and modulate T-cell phenotype and function indirectly. For example, it has been shown that non-mucosal dendritic cells can take up and deliver RA to T cells to up-regulate gut-homing molecule expression. 51 Therefore, it is possible that RA modulates donor T-cell function indirectly through DCs. In addition, our data do not exclude that other RAR isoforms, namely RAR-β and RAR-γ, may also participate in mediating RA signaling and contribute to the pathogenesis of acute GVHD in the gastrointestinal tract. Nonetheless, these results suggest that blockade of RAR-α signaling with small molecule inhibitors or through other approaches may be a clinically relevant strategy to reduce the priming of gut-homing donor T cells and selectively prevent or mitigate GVHD in the colon. We should note, however, our results differ somewhat from those reported by Nishimori and colleagues 52 who noted that administration of AM80, a synthetic retinoid that binds to both RARα and RARβ, resulted in a reduction in GVHD severity in the skin, and did not exacerbate pathological damage in the colon. Of note, the authors employed a murine model of chronic GVHD in which cutaneous and not visceral manifestations of GVHD are most pronounced as opposed to the acute model utilized in the current
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studies. Thus, it is formally possible that the effects of RAR-α signaling blockade may vary to some extent in the setting of acute versus chronic GVHD. Further studies will be necessary to determine if this is indeed the case.
In summary, these studies identify RA as a critical molecule that plays a major role in the regulation of gut-homing molecule expression and, by extension, the pathophysiology of GVHD in the gastrointestinal tract. Manipulation of the RA signaling pathway may therefore represent a novel strategy to mitigate the severity of colonic GVHD and reduce overall mortality. Finally, our results suggest that the vitamin A status of the recipient can significantly affect the ability of T cells to traffic into the colon. Consequently, determination and/or modification of vitamin A levels in patients may be useful for the prognostication of GVHD severity in the colon as well as may represent a less toxic, non-pharmacological approach by which GVHD can be successfully modulated. Cohorts of mice were then treated with either DMSO (n=8) or RA (n=8). Mice in both groups were yield an equivalent T cell dose)(n= 5). Overall survival and whole body distribution of A20-luc cells using in vivo BLI is depicted.
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